{"filing":{"accession_number":"0001554855-26-001933","cik":"0000888721","ticker":"TRIB","company_name":"TRINITY BIOTECH PLC","form":"6-K","filing_date":"2026-08-28","report_date":"2026-08-28","primary_document":"MainDocument.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/888721/000155485526001933/MainDocument.htm"},"events":[{"id":30421,"run_id":27880,"accession_number":"0001554855-26-001933","anchor_item_number":"EX-99.1","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"The exhibit discloses that Trinity Biotech received a Nasdaq staff determination letter on August 28, 2026, notifying the company that it failed to regain compliance with the market value of publicly held shares (MVPHS) requirement of $15 million by the August 18, 2026 deadline. The company's securities are now subject to suspension/delisting unless it requests and obtains a hearing before a Nasdaq Hearings Panel. This is a material delisting risk disclosure under Item 3.01 equivalent, as the company faces imminent delisting absent successful remediation or panel extension.","company_name":"TRINITY BIOTECH PLC","ticker":"TRIB","filing_date":"2026-08-28","form":"6-K","submitted_at":null,"items":[{"id":33002,"accession_number":"0001554855-26-001933","item_number":"EX-99.1","item_title":"ex991_1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The exhibit discloses that Trinity Biotech received a Nasdaq staff determination letter on August 28, 2026, notifying the company that it failed to regain compliance with the market value of publicly held shares (MVPHS) requirement of $15 million by the August 18, 2026 deadline. The company's securities are now subject to suspension/delisting unless it requests and obtains a hearing before a Nasdaq Hearings Panel. This is a material delisting risk disclosure under Item 3.01 equivalent, as the company faces imminent delisting absent successful remediation or panel extension.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-28T21:25:45.268674+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33002,"accession_number":"0001554855-26-001933","item_number":"EX-99.1","item_title":"ex991_1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The exhibit discloses that Trinity Biotech received a Nasdaq staff determination letter on August 28, 2026, notifying the company that it failed to regain compliance with the market value of publicly held shares (MVPHS) requirement of $15 million by the August 18, 2026 deadline. The company's securities are now subject to suspension/delisting unless it requests and obtains a hearing before a Nasdaq Hearings Panel. This is a material delisting risk disclosure under Item 3.01 equivalent, as the company faces imminent delisting absent successful remediation or panel extension.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-28T21:25:45.268674+00:00","company_name":"TRINITY BIOTECH PLC","ticker":"TRIB","filing_date":"2026-08-28"}]}